- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 23, 2023
Deals
Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
BioCentury | May 24, 2021
Product Development
NGM pivots to ophthamology, cancer as NASH failure raises questions about fibrosis endpoint
NGM appears set to move on from NASH after aldafermin missed the primary endpoint in the Phase IIb ALPINE 2/3 trial, but further analyses from the trial will be needed to help explain whether a
Items per page:
1 - 4 of 4